共 389 条
[1]
Abidoye OO(2006)A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) J Clin Oncol 24 5568-2190
[2]
Cohen EE(2007)Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib J Clin Oncol 25 2184-7356
[3]
Wong SJ(2002)Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 7350-2514
[4]
Kozloff MF(2008)Biomarkers in early clinical trials: the committed and the skeptics Clin Cancer Res 14 2512-11
[5]
Nattam SR(1999)Towards prediction and modulation of treatment response Radiother Oncol 50 1-20
[6]
Stenson KM(2002)Epidermal growth factor receptor as a therapeutic target in head and neck cancer Semin Radiat Oncol 12 11-1074
[7]
Blair EA(2008)A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer Ann Oncol 19 1068-543
[8]
Day S(2008)A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533-25
[9]
Dancey JE(2005)The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 18-4176
[10]
Vokes EE(2006)Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas J Clin Oncol 24 4170-8108